Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Cabozantinib,CaboStudy001,2022,USA,MDV,350,68,32,68,27.5,45,85,22,15,30,40,15,55,25,15,5,20,35,45,18,8,4,10,6,12,28,35,Gemcitabine + Cisplatin,Paclitaxel + Carboplatin,5-FU + Leucovorin,Capecitabine,5,3,2,40,60,55,15,45,40,60,2
Cabozantinib,CaboStudy002,2023,Canada,Claim Database,420,72,38,62,28.1,52,78,25,12,28,45,15,50,30,15,5,18,32,50,22,10,5,12,7,15,32,40,Docetaxel + Cisplatin,Pemetrexed + Carboplatin,Gemcitabine,Vinorelbine,6,4,3,45,65,60,20,50,30,65,3
Cabozantinib,CaboStudy003,2023,UK,MDV,280,65,40,60,26.8,38,90,20,18,32,35,15,60,20,15,5,22,38,40,15,7,3,9,5,10,25,30,Cisplatin + Etoposide,Carboplatin + Etoposide,Epirubicin + Cyclophosphamide,Docetaxel,4,2,1,35,55,50,10,40,50,70,2
Cabozantinib,CaboStudy004,2024,Germany,Claim Database,480,70,35,65,29.0,48,80,23,14,29,42,15,52,28,15,5,19,33,48,20,9,4,11,6,13,30,38,FOLFOX,FOLFIRI,Oxaliplatin,Irinotecan,7,5,4,42,62,58,18,48,34,63,3
